GILD vs. UTHR: Gilead Sciences vs. United Therapeutics Stock Comparison
How do Gilead Sciences (GILD) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Gilead Sciences (GILD) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | GILD | UTHR |
|---|---|---|
| Name | Gilead Sciences Inc. | United Therapeutics Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 207.00 billion USD | 23.94 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 22, 1992 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GILD | UTHR |
|---|---|---|
| Total Return (1Y) | 45.69% | 28.77% |
| Total Return (3Y, Annualized) | 35.30% | 37.63% |
| Total Return (5Y, Annualized) | 25.00% | 23.78% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GILD | UTHR |
|---|---|---|
| Volatility (1Y, Annualized) | 27.57% | 35.00% |
| Beta (5Y) | 0.36 | 0.49 |
| Max Drawdown (5Y) | -26.59% | -33.00% |
| Avg. Volume (3M) | 5.98M | 694.55K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GILD | UTHR |
|---|---|---|
| Sharpe Ratio (1Y) | 1.50 | 0.70 |
| Sortino Ratio (1Y) | 2.48 | 1.29 |
Profitability
ROE (TTM)
Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-22.45%
- Max
- 109.18%
- Q3
- 6.23%
- GILD
- -22.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.13%
- Max
- 109.18%
- UTHR
- 19.13%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile United Therapeutics (UTHR) reports 38.61%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.46%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- GILD
- -12.46%
- Min
- -17.05%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.61%
- UTHR
- 38.61%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Gilead Sciences (GILD) at 42.43% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
42.43%
- Max
- 83.12%
- GILD
- 42.43%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.99%
- Max
- 83.12%
- UTHR
- 28.99%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GILD | UTHR |
|---|---|---|
| ROE (TTM) | -22.45% | 19.13% |
| ROA (TTM) | 13.47% | 10.91% |
| Net Margin (TTM) | -12.46% | 38.61% |
| Operating Margin (TTM) | 42.43% | 28.99% |
| Gross Margin (TTM) | 79.95% | 86.34% |
Growth
Revenue Growth
Both Gilead Sciences (GILD) at 2.39% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than United Therapeutics (UTHR) at 13.07%, which is closer to a typical peer reading.
Growth Metrics
| Metric | GILD | UTHR |
|---|---|---|
| Revenue Growth (YoY) | 2.39% | 10.61% |
| Revenue Growth (3Y CAGR) | 2.57% | 18.02% |
| EPS Growth (YoY) | 1,684.21% | 13.07% |
| EPS Growth (3Y CAGR) | 23.04% | 22.92% |
Financial Strength
Current Ratio (MRQ)
United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GILD
- 1.38
- Min
- 0.10
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- UTHR
- 4.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Gilead Sciences (GILD) carries debt-to-equity ratio of 2.02 against its industry range, while United Therapeutics (UTHR) reports no figure this period.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.02
- GILD
- 2.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- UTHR
- --
Financial Strength Metrics
| Metric | GILD | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 1.38 | 4.61 |
| Debt / Equity (MRQ) | 2.02 | -- |
| Net Debt / EBITDA | 1.25 | -1.53 |
Dividends
Dividend Yield (TTM)
United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- GILD
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
United Therapeutics (UTHR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.46%
- GILD
- 43.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GILD | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 1.94% | 0.00% |
| Dividend Payout Ratio (TTM) | 43.46% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- GILD
- --
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.22
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- UTHR
- 21.22
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Gilead Sciences (GILD) at 6.68 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- GILD
- 6.68
- Q1
- 3.01
- Min
- 0.01
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.51
- Max
- 58.18
- Q3
- 25.77
- UTHR
- 7.51
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.88
- GILD
- 15.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.80
- Max
- 13.53
- Q3
- 6.54
- UTHR
- 3.80
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GILD | UTHR |
|---|---|---|
| P/E Ratio (TTM) | -- | 21.22 |
| P/S Ratio (TTM) | 6.68 | 7.51 |
| P/B Ratio (MRQ) | 15.88 | 3.80 |
| Free Cash Flow Yield (TTM) | 5.16% | 1.90% |